Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin for Severe Gram-positive Infections in PWUD
NCT04847921Phase 3Terminated
- Sponsor
- University of Colorado Denver
- Start
- Apr 2021
- Primary completion
- Oct 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalbavancin in Gram-positive bacterial infection, sponsored by University of Colorado Denver. Started Apr 2021; status: terminated.
02
Drugs
dalbavancin
03
Conditions
Gram-positive bacterial infection
Beyond the preview
Go deeper on NCT04847921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847921.